PCM
RIGL icon

Prelude Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Prelude Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,890
Closed -$183K – 2160
2021
Q4 		$183K Sell
6,890
-2,910
-30% -$87.8K ﹤0.01% 1589
2021
Q3 		$356K Hold
9,800
– – 0.01% 1055
2021
Q2 		$425K Buy
9,800
+1,300
+15% +$49.1K 0.01% 1035
2021
Q1 		$291K Hold
8,500
– – 0.01% 1164
2020
Q4 		$298K Hold
8,500
– – 0.01% 916
2020
Q3 		$204K Buy
8,500
+2,500
+42% +$61.4K 0.01% 689
2020
Q2 		$110K Buy
+6,000
New +$108K 0.01% 921
2020
Q1 		– Sell
-476
Closed -$10K – 1938
2019
Q4 		$10K Sell
476
-75
-14% -$1.54K ﹤0.01% 1708
2019
Q3 		$10K Sell
551
-404
-42% -$8.35K ﹤0.01% 1495
2019
Q2 		$25K Buy
955
+312
+49% +$7.04K ﹤0.01% 1254
2019
Q1 		$17K Sell
643
-101
-14% -$2.31K ﹤0.01% 1341
2018
Q4 		$17K Buy
744
+56
+8% +$1.58K ﹤0.01% 1273
2018
Q3 		$22K Buy
688
+61
+10% +$1.83K ﹤0.01% 1294
2018
Q2 		$18K Buy
627
+36
+6% +$1.28K ﹤0.01% 1374
2018
Q1 		$21K Buy
591
+29
+5% +$1.16K ﹤0.01% 1258
2017
Q4 		$22K Buy
+562
New +$21.4K ﹤0.01% 1123
2017
Q3 		– Sell
-969
Closed -$26K – 1862
2017
Q2 		$26K Buy
969
+489
+102% +$13.4K ﹤0.01% 1201
2017
Q1 		$16K Buy
480
+440
+1,100% +$11.2K ﹤0.01% 1306
2016
Q4 		$1K Sell
40
-410
-91% -$11.7K ﹤0.01% 1500
2016
Q3 		$17K Sell
450
-2,450
-84% -$70.2K ﹤0.01% 1365
2016
Q2 		$65K Buy
2,900
+410
+16% +$10.2K 0.01% 905
2016
Q1 		$52K Buy
2,490
+420
+20% +$10.4K 0.01% 967
2015
Q4 		$63K Sell
2,070
-935
-31% -$28.3K 0.01% 982
2015
Q3 		$74K Buy
3,005
+2,530
+533% +$75.5K 0.01% 931
2015
Q2 		$15K Buy
+475
New +$18.1K ﹤0.01% 1507

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's RIGL Position: Q1 2022 in Review

Prelude Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 6,890 shares — an estimated $183K sold.

Prelude Capital Management first reported a position in RIGL in Q2 2015 and held it in 25 quarters. The position peaked at $425K in Q2 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • Prelude Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Prelude Capital Management sold 6,890 Rigel Pharmaceuticals shares in Q1 2022, an estimated $183K.
  • Prelude Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2015 and held it in 25 quarters.
  • Prelude Capital Management's Rigel Pharmaceuticals position peaked at $425K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.